Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.
Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
A podcast hosted by Shikha Jain, MD, FACP, covering modern day health care in an ever-evolving world. Watch 2024 episodes on Healio today.
An abstract is unavailable.
The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported…
Navigate the evolving paradigms in advanced ovarian cancer care. Delve into the latest treatments and methodologies improving patient outcomes.
The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
The FDA approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.
Late-breaking abstracts feature substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at…
